EDP-235 clinical trials
Also written EDP-235.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses EDP-235 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- EDP-235
- 4
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses EDP-235 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19CompletedPhase 2Enanta Pharmaceuticals, IncNCT05616728Written as EDP-235How we know
- Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.CompletedPhase 1Enanta Pharmaceuticals, IncNCT05594602Written as EDP-235How we know
- Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT05594615Written as EDP-235How we know
- A Study of EDP-235 in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT05246878Written as EDP-235How we know